Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temtokibart - LEO Pharma

Next Previous
Drug Profile

Temtokibart - LEO Pharma

Alternative Names: AGRX-112; ARGX 112; LEO 138559; LP-0145

Latest Information Update: 16 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator argenx
  • Developer LEO Pharma
  • Class Anti-inflammatories; Antianaemics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 22 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Research Anaemia

Most Recent Events

  • 16 May 2025 LEO Pharma completes phase-II clinical trials in Atopic dermatitis in United Kingdom, Spain, Romania, Japan, France, Poland, Germany, Hungary, Czech Republic, USA, Canada (SC) (EudraCT2022-500777-14-00)(NCT05923099)
  • 09 May 2025 Adverse events data from phase-II clinical trials in Atopic dermatitis released by LEO Pharma
  • 26 Sep 2024 Early research in Anaemia in Denmark (Parenteral) before September 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top